The Effective Application of Biased Signaling to New Drug Discovery

Terry Kenakin Ph.D.

Department of Pharmacology
University of North Carolina School of Medicine
120 Mason Farm Road
Room 4042 Genetic Medicine Building, CB# 7365
Chapel Hill, NC 27599-7365
Phone: 919-962-7863
Fax: 919-966-7242 or 5640
Email: kenakin@email.unc.edu
Running Title: Applying Biased Signaling to Drug Discovery

Terry Kenakin Ph.D.
Department of Pharmacology
University of North Carolina School of Medicine
120 Mason Farm Road
Room 4042 Genetic Medicine Building, CB# 7365
Chapel Hill, NC 27599-7365
Email: kenakin@email.unc.edu

Text pages 12
Tables 0
Figures 5
References 63
Abstract 182
Introduction 275
Discussion 3021

Abbreviations: GR89696: methyl 4-[2-(3,4-dichlorophenyl)acetyl]-3-(pyrrolidin-1-ylmethyl)piperazine-1-carboxylate. TRV120027: Sar-Arg-Val-Tyr-Ile-His-Pro-D-Ala-OH. 6′-GNTI: 6′-guanidino-17-(cyclopropylmethyl)-6,7-didehydro-4,5α-epoxy-3,14-dihydroxyindolo[2′,3′:6,7]morphinan. Salvanorin B: (2S,4aR,6aR,7R,9S,10aS,10bR)-2-(3-furanyl)dodecahydro-9-hydroxy-6a,10b-dimethyl-4,10-dioxo-methyl ester-2H-naphtho[2,1-c]pyran-7-carboxylic acid. Salvanorin A: methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-acetyloxy-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate. RB-64: Methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-9-(2-thiocyanatoacetyl)oxy-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate. RB-65
Abstract: The ability of agonists to selectively activate some but not all signaling pathways linked to pleiotropically signaling receptors has opened the possibility of obtaining molecules that emphasize beneficial signals, de-emphasize harmful signals and concomitantly de-emphasize harmful signals while blocking the harmful signals produced by endogenous agonists. The detection and quantification of biased effects is straightforward but two important factors should be considered in the evaluation of biased effects in drug discovery. The first is that efficacy, and not bias, determines whether a given agonist signal will be observed; bias only dictates the relative concentrations at which agonist signals will appear when they do appear. Therefore, a Cartesian co-ordinate system plotting relative efficacy (on a scale of Log relative Intrinsic Activities) as the ordinates and Log(bias) as the abscissae is proposed as a useful tool in evaluating possible biased molecules for progression in discovery programs. Second, it should be considered that the current scales quantifying bias limit this property to the allosteric vector (ligand/receptor/coupling protein complex) and that whole cell processing of this signal can completely change measured bias from in vitro predictions.
Introduction

Over the last 20 years in Pharmacology evidence has accumulated to indicate that agonists need not activate all signaling pathways linked to pleiotropically coupled receptors but in fact may emphasize signaling to some pathways more than, and at the expense of, others; this is referred to as biased receptor signaling. The key to the appreciation of this concept was the introduction of new functional assays in pharmacology that allowed the separate observance of the various processes mediated by seven transmembrane receptors (7TMRs). As these assays were employed in recombinant and natural systems, literature reports began to emerge to suggest that not all systems had a monotonic stimulus-response linkage that made agonist potency ratios cell-type independent i.e. that receptor activation was uniform. These effects augured the concept of bias and became appreciated as a therapeutic way forward, i.e. ‘The possibility is raised that selective agonists and antagonists might be developed which have specific effects on a particular receptor-linked effector system’ (Roth and Chuang, 1987). The first molecular description of this phenomenon ascribed this effect to the stabilization of different receptor active states by different agonists (Kenakin and Morgan, 1989; Kenakin, 1995). The ability of agonists to choose signaling pathways has been given a number of names (‘stimulus trafficking’; Kenakin, 1995; ‘functional selectivity’; Lawler et al, 1999; Kilts et al, 2002; Shapiro et al, 2003; ‘functional dissociation’; Whistler et al, 1999; ‘biased inhibition’; Kudlacek et al, 2002; differential engagement, Manning, 2002); the name ‘biased signaling’ was introduced by Jarpe et al
1998 and is favored as a general descriptor of the effect. It is worth considering the present place of this idea in new drug discovery.

**Therapeutic Applications of Signaling Bias**

While there are quantitative scales to characterize biased signaling (*vide infra*), the effect can readily be seen with no arithmetic manipulation of data through a bias plot; this expresses the response to an agonist in one signaling pathway as a function of the observed agonist response in another pathway. When signaling is seen with this tool, almost all ligands are biased because of the varying sensitivities of different functional assays and varying efficiency of coupling of receptor populations to different signaling proteins in the cell; this is system bias. This type of cellular bias will be imposed on all agonists operating within the two systems being studied and thus would not be useful therapeutically. However, within this system bias there may be unique ligand-selective signaling bias in the form of diverging bias plot curves seen for any two pathways; this is the ligand bias that has potential for production of selective therapeutic effect. This is illustrated in Fig 1 where the G protein and β-arrestin activating properties of κ-opioid ligands are shown on a bias plot and a clear differentiation is shown between agonists (White et al, 2014). Ligand-mediated receptor biased signaling must be explicitly defined and differentiated from simple differences in ligand effect for different functional assays but if this can be done, then a potentially therapeutically applicable ligand property can be associated with a chemical scaffold and subsequently optimized.

In drug discovery, there are generally three reasons for seeking biased ligands:
1. **The emphasis of a favorable cellular signal** i.e. β-arrestin-2 activation for parathyroid agonists in osteoporosis (Ferrari et al, 2005; Gesty-Palmer et al, 2006; 2009) and β-arrestin-1 activation for GLP-1 effect in diabetes (Sonoda et al, 2008).


3. **The de-emphasis of a debilitating cellular signal and the blockade of the ability of the natural agonist to produce the same signal**, i.e. TRV120027 blockade of angiotensin-mediated vasoconstriction in heart failure with concomitant preservation of angiotensin-mediated β-arrestin signaling (Violin et al, 2006; 2010).

**Quantifying Bias**

While a bias plot can be used to detect unique ligand-mediated signaling bias, it cannot quantify such effects. Within any structure-activity relationship for bias this latter step is important in furnishing a scale by which medicinal chemists can gauge progress towards or away from a defined signaling pathway. Such a scale can be derived from the Black/Leff operational model of agonism (Black and Leff, 1983) which furnishes estimates of affinity in the form of $K_A$ values (equilibrium dissociation constants of agonist-receptor complexes) and agonist efficacy (in the form of $\tau$ values for a given signaling pathway). A null method to derive such a factor (termed RA, denoted as Receptor Activity) has been published (Ehlert et al, 1999) and subsequently applied to
agonist bias (Griffin et al, 2007; Figueroa et al, 2008; Tran et al, 2009; Ehler et al, 2011). A modification and extension of this approach amenable to the statistical comparison of multiple agonists to yield $\Delta \Delta \log(\tau/K_A)$ values (denoted as transducer coefficients) has been published to furnish logarithms of bias factors between signaling pathways (Kenakin et al, 2012). Transducer coefficients are based on allosteric constants between ligands, receptors and signaling-proteins and thus yield bias within the allosteric vector defined by this ternary complex (Kenakin and Christopoulos, 2012); this makes the values independent of cell type and useful for quantification of biased effects. Calculation of transducer coefficients for the $\kappa$-opioid agonists shown in Fig 1 indicate bias values of 4.3-fold toward G Protein for GR89696 and 26.4-fold toward $\beta$-arrestin for RB64 when compared to Salvinorin A.

While these values are certainly useful to identify unique molecular modes of action and for visualizing the relative concentration-dependence of biased signals when the efficacy of the ligand is sufficient to demonstrate agonism, they do not in themselves assist in the prediction of actual biased response; this still lies within the realm of relative intrinsic efficacy. Because of this fact, it is useful to assess biased ligands in terms of a Cartesian coordinate system of relative efficacy on an ordinate scale as a function of bias on the abscissal scale. Fig 2 shows such a presentation of the relative ability of 30 $\kappa$-opioid agonists to produce G protein vs $\beta$-arrestin response (on a scale of $\log(\text{Intrinsic Activity}_{\text{G-Protein}} / \text{Intrinsic Activity}_{\text{B-Arrestin}})$ where Intrinsic Activity is the maximal response to the agonist in the assay -Ariens et al, 1954) as a function of the $\log(\text{Bias})$ for these responses ($\Delta \Delta \log(\tau/K_A)$ values). It can be seen that a considerable scatter results reflecting variance in the efficacy and affinity of these ligands for the
receptor as it interacts with different signaling systems. Such an array is useful for choosing ligands that are more prone to produce desired responses vs those more prone to block undesired responses. For instance, it can be seen that relatively similar values of bias can yield compounds of differing ability to produce response as in the case of RB-65 and RB-64 and separately for 6'-GNTI and Salvinorin B.

Since seven transmembrane receptors are allosteric proteins, their affinity for ligands depends on the nature and concentration of co-binding species; different co-binding ligands have been shown to affect the receptor affinity of ligands in accordance with this allosteric reciprocity (i.e. salvanorin affinity for κ-opioid receptors with G\(_{\alpha 16}\) vs G\(_{\alpha i2}\); Yan et al, 2008 and changes in ghrelin receptors with addition of β-arrestin to nanodiscs, Mary et al, 2012). In view of the fact that functional response depends on the ternary complex of agonist-receptor-signaling protein (Onaran and Costa, 2012), it is conceivable that the affinity of the receptor-signaling complex shows variable affinity for agonists depending on the nature of the signaling protein interacting with the receptor. This raises the possibility that agonists may have different affinities for the receptor depending on which signaling pathway is being activated. In fact, significantly different functional affinities for partial agonists have been shown for 5-HT\(_{2A}\) receptor agonists activating G proteins vs producing ERK phosphorylation (Strachan et al, 2010). Very different EC\(_{50}\) values for partial agonists also have been reported for μ opioid receptors (McPherson et al, 2010; Nickolls et al, 2011), histamine H4 receptors (Nijmeijer et al, 2012), and β\(_1\)-adrenoceptors (Casella et al, 2011). This suggests that effective bias may be obtained through combinations of efficacies and affinities for the receptor as it interacts with different pathways. Fig 3 shows two hypothetical agonists
both designed to produce G protein agonism (solid lines) and little β-arrestin activation (dotted lines). Interestingly, two very different values for bias could still yield favorable effects in terms of de-emphasizing β-arrestin signaling; agonist A ($\Delta \Delta \log (\tau/K_A) = -1.8$) produces G protein activation but little β-arrestin activation. However, agonist A would be a relatively poor antagonist of the natural agonist activation of β-arrestin. In contrast, agonist B ($\Delta \Delta \log (\tau/K_A) = 2.2$) produces G protein activation, no β-arrestin activation and also would be a selective antagonist of the natural agonist in activating β-arrestin.

The consideration of possible biased affinity raises another condition seen in discovery programs aimed at biased molecules, namely those compounds which may not have sufficient efficacy to generate a response in one of the signaling pathways. This is frequently observed for β-arrestin assays and has erroneously been described as ‘perfect bias’. Usually there are no independent data to conclude that such molecules may not produce a response in more sensitive tissues therefore it is important to estimate a possible bias value for these molecules. A lower limit for bias can be estimated by utilizing the molecule as an antagonist for a more efficacious agonist and determining the affinity of the test molecule; this will be the EC$_{50}$ of that molecule in more sensitive assays for the signaling pathway of the molecule when it produces partial agonism. Then an estimate of bias can be obtained by assuming a 5% error on the ability of the assay to detect an agonist response, setting the maximal response to be 0.05 in calculation of a Relative Activity (for use in an analysis if $\Delta \Delta \log (RA)$) through a calculation of $\log (0.05/K_B)$ where $K_B$ is the antagonist value for blockade by the molecule of the signaling pathway. The resulting $\Delta \Delta \log (RA)$ value is a lower limit for bias, i.e. bias will be at least this value or more—this procedure is
illustrated in Fig 4. A useful and rigorous procedure for this estimation also has been recently been published (Stahl et al, 2015).

The System Independence of Transducer Coefficients

Agonist values of $\Delta \Delta \text{Log}(\tau/KA)$ are dependent on the allosteric co-operativity constants controlling the interaction of agonists, receptors and individual signaling proteins (Kenakin, 2013). Thus the agonist $K_A$ reflects the change in the natural affinity of the receptor for the signaling protein in the absence vs the presence of agonist in the form of the allosteric parameter $\alpha$ (Stockton et al, 1983; Ehlert, 1988) and the efficacy $\tau$ is the change in efficacy of interaction between the receptor and signaling protein in the absence and presence of the agonist (denoted $\beta$ in the functional allosteric model, Kenakin, 2005; Ehlert, 2005; Price et al, 2005; denoted as ‘B’ in Ehlert(1988)). Under these circumstances, the transducer coefficient is unique to the allosteric vector made up of agonist/receptor/signaling protein and is thus cell type and system independent. Therefore, full agonist potency ratios ($\Delta \Delta \text{Log}(\tau/K_A)$ for full agonists) should not vary when measured in different cell types if the response is solely dependent only on a signal emanating from the allosteric vector with no modification by the cell. However, cell type and system variation of agonist potency ratios have long been documented thereby indicating that receptor stimulus may, in some cases, be considerably modified by the cell (i.e. calcium entry, ERK phosphorylation, label free drug response such as DMR or cell layer electrical impedance etc.). For instance, the relative potency ratios of the calcitonin agonists human and porcine calcitonin and human CGRP vary by orders of magnitude when the receptor is transfected into COS vs CHO cells (Christmanson et
Agonist mediated β-adrenoceptor agonist potency ratios measured at the allosteric vector (cyclic AMP) and from the whole cell response (cellular impedance) have been shown to vary thereby indicating a modification by the cell (Peters et al, 2007). Even modification of host cell background such as co-expression of Gαs protein in HEK 293 cells has been shown to reverse calcitonin receptor agonist potency ratios for Eel and Porcine calcitonin (Watson et al, 2000). These effects strongly suggest that bias values measured in vitro may not always predict therapeutic biased signaling in vivo and bring into question how measured bias can be used to progress drug candidate molecules.

It is useful to consider how bias numbers can effectively be applied to drug discovery in light of their sometimes dubious predicting power for therapeutic effect. Before biased signaling was considered as a pharmacological mechanism, new molecules detected in highthroughput screens were sorted on the basis of potency and advanced into more complex and resource demanding models. With the advent of bias has come the ability to retest the active molecules found in a highthroughput screen in a functional test for another signaling pathway to identify biased molecules. This practice allows the detection of signaling bias resulting in the advancement of molecules that are known to stabilize different receptor active states. These molecules would be known to be different on a molecular level and progression to the next pharmacological model and in vivo testing would therefore increase the likelihood of detecting truly different in vivo phenotypic therapeutic activity. In addition, if a favorable in vivo phenotype is discovered, then the linking of that phenotype to in vitro bias assays furnishes pharmacologists and medicinal chemists with the tools to optimize the activity; it is
within this realm that $\Delta \Delta \log(\tau/K_A)$ values yield the scale to constructively track changes in signaling bias with chemical structure.

There are other possible applications of transducer ratios that actually take advantage of the cell-type variability effect. One is for the screening of biased molecules. This is because cell-based variance in agonist potency ratios occurs only in cases where the agonists produce a biased signal from the allosteric receptor-based vectors. Therefore, if a high-throughput screen is carried out in two separate assays of cellular response (i.e. label free screening in two cellular backgrounds), then the relative potencies of only the biased ligands will diverge between the two cell backgrounds. A second possible application would be to use transducer coefficients to identify unique cell-based activity. For example, Fig 5 shows a bias plot of the agonist activity of five dopamine agonists for naturally dopamine D1 receptors in U-2 and SK-N-MC cells (Peters and Scott, 2009). It can be seen that while four of the agonists have comparable activity in the two cell types, A77636 diverges to have an 11-fold bias toward U-2 cells. While in this case it is difficult to ascribe a physiological significance to these data, the same effect seen in a comparison of two physiologically meaningful cell types (i.e. tumor vs healthy cells, normal cells vs cells from a heart failure model) could possibly identify pathologically-selective ligands with unique activity. This modification of allosteric vector signals can extend beyond cell type to cell state (i.e. uterine smooth muscle in pregnancy, state of oestrous etc or cell viability in disease states).

**NAM- and PAM-Induced Bias**
Agonists for pleiotropic receptors show an array of efficacies, i.e. pluridimensional efficacy (Galandrin and Bouvier, 2006) as different signaling patterns are activated in varying degrees. Thus, agonist efficacy towards the whole cell has a quality as well as a quantity. Representations of these different qualities of efficacy can be shown on a multi-axis plot (referred to as 'web plots', 'radar plots' or 'spider plots'); for example, ligand-specific webs of efficacy have been shown for β-adrenoceptors (Evans et al, 2010) and κ-opioid receptors (Zhou et al, 2013). The questions of efficacy quality and biased signaling become relevant to the interaction of 7TMR ligands and allosteric molecules.

The increase in functional, vs binding, screens in discovery programs has increased the likelihood of obtaining an allosteric molecule (Rees et al, 2002). Allosteric molecules for 7TMRs that can reduce signaling (negative allosteric molecules, NAMs) or potentiate signaling (positive allosteric modulators, PAMs) are becoming increasingly important as potential therapeutic entities. Since allosteric molecules are by nature permissive in that they may allow the interaction of the receptor with the natural agonist, there is a probability that the allosteric ligand will change the quality of the natural agonist signaling, i.e. will produce a bias for the natural agonist effect. Such bias has been noted for NAMs in the selective blockade of NK2 receptors (Maillet et al., 2007), prostaglandin D2 receptors (Mathiesen et al., 2005), calcium sensing receptors (Cook et al., 2015; Davey et al., 2012) and PAMs for GLP-1 receptors (Koole et al., 2010) and mGlutamic acid 5 receptors (Bradley et al., 2011). The possibility of producing induced-bias in natural signaling can be viewed as a potential positive aspect of
allosteric modulation of drug effect but also should be seen as an added consideration in the development of allosteric molecules.

**Bias as a Perspective in Discovery**

The ability of ligands to produce portions of a given receptors signaling portfolio has increased the scope for selective 7TMR-based new drugs. It might be asked whether biased signaling is a rare or common phenomenon and whether it will impact 7TMR therapeutics. In light of a molecular dynamics view of 7TMR function, the expectation of biased signaling would be predicted to be a common, not rare, phenomenon. Specifically, molecular dynamics describes receptor systems as comprised of ensembles of numerous receptor states the inter-conversion of which can be modeled as the receptor rolling on an energy landscape of conformations (Fraunfelder, 1991; Freire, 1998; Hilser et al, 1998; 2006; Hilser and Thompson, 2007). Seen in terms of this hypothesis, the cell interacts with a spontaneous ensemble in the absence of a ligand and a ligand-formed ensemble in the presence of the ligand. This ensemble is comprised of the stabilized conformations dictated by the individual affinities the ligand has for the various receptor states (Onaran and Costa, 1997; Onaran et al, 2000; Kenakin, 2002). For identical ligand-stabilized ensembles to be created would mean that two ligands would have to have *identical* affinities for every conformation in the ensemble, a statistically unlikely event. Therefore, it would be predicted that different ligands would form at least slightly different ensembles which, in turn, would lead to different bias for signaling proteins. However, this expectation would need to be tempered with the fact that only a few conformations are associated with cell signaling thus the chance that these would vary with ligands may not be as high as for
total ensembles. In general, however, molecular dynamics predicts that biased signaling might be fairly common and inherent property of 7TMR-ligand systems.

Conclusions

The existing data on agonist signaling suggests that bias is a prevalent pharmacological phenomenon that should be considered in all new drug discovery programs. Bias can readily be measured and quantified through simple in vitro experiments utilizing scales such as $\Delta \Delta \log(\tau/K_A)$ but it should be recognized that cell type and physiological context may change these numbers and with that, the predictions that bias measurements make. In addition, the realization that bias is an amalgam of efficacy and affinity differences introduces concepts of affinity- vs efficacy-dominant bias ligands. This opens the possibility of biased antagonism as a viable therapeutic option. Finally, it can no longer be assumed that a synthetic agonist or antagonist or an allosteric modulator for a receptor will not alter the quality of efficacy produced by the natural agonist(s). This makes it incumbent upon drug discovery efforts to pharmacologically characterize new drug activity with multiple functional assays and with quantitative scales. While there are simple tools available to do this, the modification of these measured differences in signaling by cell type and other factors in vivo presently make direct prediction of biased signaling to therapeutic systems still a challenging prospect.
Acknowledgements:

I wish to thank the ever stimulating Bryan Roth lab at UNC for discussion and inspiration, Arthur Christopoulos for thoughts bounced back a little differently and Kate White for an excellent set of data.

Authorship Contribution: Authorship solely Terry Kenakin
References


Figure Legends

Fig 1 Bias plot for three κ-opioid agonists. Ordinates are agonist-mediated fractional recruitment of β-arrestin measured in the Tango assay and abscissae are fractional activation of G\textsubscript{ai} protein through a firefly luciferase cyclic AMP assay. A relatively unbiased response is produced by Salvanorin A while a response biased toward β-arrestin is produced by GR89696 ($10^{\Delta \Delta \log (\tau/K_A)}$ relative to Salvanorin A = 4.3) and a response biased toward G\textsubscript{ai} protein is produced by RB64 ($10^{\Delta \Delta \log (\tau/K_A)}$ relative to Salvanorin A = 26.4). Data from White et al, 2013.

Fig 2 Activity of 30 agonists for κ-opioid receptors. Ordinates are logarithms of the relative intrinsic activity (maximal response) of the agonists for G Protein/β-Arrestin. Abscissae are $\Delta \Delta \log (\log (\tau/K_A))$ values depicting bias relative to Salvinorin A. Inset concentration curves are for 2 sets of agonist with similar bias but differing agonist characteristics (solid line G protein response; dotted line β-arrestin response). Data from White et al, 2013.

Fig 3 Profiles of 2 hypothetical agonists that would be predicted to produce selective G protein (solid line concentration curves) over β-arrestin (dotted line concentration response curves). Grey open circle symbols represent the relative location of the agonists on a Log (Rel. I.A.) vs Log(Bias) plot - see fig 2. While agonist A would produce selective G protein agonism, it would not selectively block natural agonist β-arrestin signaling. Agonist B would produce selective G protein signaling, not signal
through β-arrestin and selectively prevent activation of β-arrestin by the natural agonist system.

Fig 4. Estimation of minimal bias for a ligand that produces no response. If a ligand has low efficacy for a given pathway and the assay for that pathway is of insufficient sensitivity to demonstrate agonist response, the minimal bias for that compound can still be assessed. Specifically, the ligand can be used as an antagonist and a measure of the $K_A$ can be made through antagonism. It then is assumed that the ligand produced a 5% response (possibly within error of the assay measurement) and an estimate of the limiting value of the Log($\tau/K_A$) is made. This is used for the $\Delta$Log($\tau/K_A$) and subsequently the $\Delta\Delta$Log($\tau/K_A$) measurement to yield an estimate of the minimal bias., i.e. this is the best case scenario that the ligand has efficacy for that pathway. It could have less activity in which case the bias will be greater than the minimal estimation.

Fig 5 Bias plot for the dopamine receptor mediated label free assay response to 5 agonists for endogenous dopamine D$_1$ receptors in U-2 cells (ordinates) and SK-N-MC cells (abscissae). The agonist A77636 is selectively 11-fold biased toward production of responses in U-2 cells. Data from Peters and Scott, 2009.
K-Opioid Bias Plot

% β-Arrestin Activation

% G Protein Activation

GR89696 biased toward β-Arrestin

Salvanorin A

RB64 is biased toward G Protein

FIG 1
FIG 2
$\Delta \Delta \text{Log}(\tau/K_A) = -1.8$

**Agonist A**
- Selective G Protein agonism
- Little β-Arrestin agonism
- Little interference with natural β-arrestin signal

$\Delta \Delta \text{Log}(\tau/K_A) = 2.2$

**Agonist B**
- Selective G Protein agonism
- Little β-Arrestin agonism
- Selective blockade of natural β-arrestin signal

**FIG 3**